Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,863 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.
Lin SY, Chang Hsu Y, Peng YH, Ke YY, Lin WH, Sun HY, Shiao HY, Kuo FM, Chen PY, Lien TW, Chen CH, Chu CY, Wang SY, Yeh KC, Chen CP, Hsu TA, Wu SY, Yeh TK, Chen CT, Hsieh HP. Lin SY, et al. Among authors: wu sy. J Med Chem. 2019 Nov 27;62(22):10108-10123. doi: 10.1021/acs.jmedchem.9b00722. Epub 2019 Nov 15. J Med Chem. 2019. PMID: 31560541
Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.
Mahindroo N, Huang CF, Peng YH, Wang CC, Liao CC, Lien TW, Chittimalla SK, Huang WJ, Chai CH, Prakash E, Chen CP, Hsu TA, Peng CH, Lu IL, Lee LH, Chang YW, Chen WC, Chou YC, Chen CT, Goparaju CM, Chen YS, Lan SJ, Yu MC, Chen X, Chao YS, Wu SY, Hsieh HP. Mahindroo N, et al. Among authors: wu sy. J Med Chem. 2005 Dec 29;48(26):8194-208. doi: 10.1021/jm0506930. J Med Chem. 2005. PMID: 16366601
Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
Lu IL, Huang CF, Peng YH, Lin YT, Hsieh HP, Chen CT, Lien TW, Lee HJ, Mahindroo N, Prakash E, Yueh A, Chen HY, Goparaju CM, Chen X, Liao CC, Chao YS, Hsu JT, Wu SY. Lu IL, et al. Among authors: wu sy. J Med Chem. 2006 May 4;49(9):2703-12. doi: 10.1021/jm051129s. J Med Chem. 2006. PMID: 16640330
Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach.
Wu YS, Coumar MS, Chang JY, Sun HY, Kuo FM, Kuo CC, Chen YJ, Chang CY, Hsiao CL, Liou JP, Chen CP, Yao HT, Chiang YK, Tan UK, Chen CT, Chu CY, Wu SY, Yeh TK, Lin CY, Hsieh HP. Wu YS, et al. Among authors: wu sy. J Med Chem. 2009 Aug 13;52(15):4941-5. doi: 10.1021/jm900060s. J Med Chem. 2009. PMID: 19586033
Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, Reddy R, Lin WH, Chen CH, Peng YH, Leou JS, Lien TW, Huang CT, Fang MY, Wu SH, Wu JS, Chittimalla SK, Song JS, Hsu JT, Wu SY, Liao CC, Chao YS, Hsieh HP. Coumar MS, et al. Among authors: wu sh, wu js, wu sy. J Med Chem. 2010 Jul 8;53(13):4980-8. doi: 10.1021/jm1000198. J Med Chem. 2010. PMID: 20550212
Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents.
Tung YS, Coumar MS, Wu YS, Shiao HY, Chang JY, Liou JP, Shukla P, Chang CW, Chang CY, Kuo CC, Yeh TK, Lin CY, Wu JS, Wu SY, Liao CC, Hsieh HP. Tung YS, et al. Among authors: wu js, wu sy, wu ys. J Med Chem. 2011 Apr 28;54(8):3076-80. doi: 10.1021/jm101027s. Epub 2011 Mar 24. J Med Chem. 2011. PMID: 21434659
Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.
Peng YH, Shiao HY, Tu CH, Liu PM, Hsu JT, Amancha PK, Wu JS, Coumar MS, Chen CH, Wang SY, Lin WH, Sun HY, Chao YS, Lyu PC, Hsieh HP, Wu SY. Peng YH, et al. Among authors: wu js, wu sy. J Med Chem. 2013 May 23;56(10):3889-903. doi: 10.1021/jm400072p. Epub 2013 May 10. J Med Chem. 2013. PMID: 23611691
1,863 results